Cr Pharmaceutical
Cr Pharmaceutical, officially known as China Resources Pharmaceutical Group Limited, is a leading player in the pharmaceutical industry, headquartered in Hong Kong. Established in 1992, the company has grown significantly, with a strong presence in major operational regions across China and beyond.
Specialising in the research, development, manufacturing, and distribution of a wide range of pharmaceutical products, Cr Pharmaceutical is renowned for its commitment to quality and innovation. Its core offerings include prescription medications, over-the-counter drugs, and healthcare products, all designed to meet the diverse needs of patients and healthcare providers.
With a robust market position, Cr Pharmaceutical has achieved notable milestones, including strategic partnerships and expansions that enhance its competitive edge. The company continues to focus on advancing healthcare solutions, solidifying its reputation as a trusted name in the pharmaceutical sector.
-9 vs industry average
Cr Pharmaceutical’s score of 29 is higher than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Cr Pharmaceutical?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2027
Reported emissions
Scope 3 accounts for ••• of total emissions.
Cr Pharmaceutical's reported carbon emissions
In 2024, Cr Pharmaceutical, headquartered in Hong Kong, reported total carbon emissions of approximately 722.5 million kg CO2e. This figure includes Scope 1 emissions of about 175 million kg CO2e and Scope 2 emissions of approximately 547.4 million kg CO2e. Notably, the company has not disclosed any Scope 3 emissions data. Cr Pharmaceutical has set ambitious climate commitments, aiming to reduce carbon dioxide emission intensity by 10% by the end of the 14th Five-Year Plan period (2025), compared to a baseline of 0.3184 tons/RMB 10,000 in 2020. Additionally, they plan to decrease comprehensive energy consumption per RMB 10,000 of added value by 8% within the same timeframe. Looking towards the future, Cr Pharmaceutical has committed to achieving carbon neutrality by 2050 for both Scope 1 and Scope 2 emissions. These targets are part of a broader strategy inherited from its parent company, China Resources Pharmaceutical Group Limited, which underscores the company's dedication to sustainability and climate action.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Cr Pharmaceutical’s Climate Goals (2030 & 2050)
4 goals2050
We aim to achieve carbon neutrality by 2050
We aim to achieve carbon neutrality by 2050.
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 4 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
Cr Pharmaceutical
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project